Next Article in Journal
Protein Kinase A Distribution Differentiates Human Glioblastoma from Brain Tissue
Next Article in Special Issue
Kinases and Cancer
Previous Article in Journal
Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics
Previous Article in Special Issue
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors

JNK, p38, ERK, and SGK1 Inhibitors in Cancer

Department for Microbiology, Immunbiology und Genetics, Max F. Perutz Laboratories, University of Vienna, Vienna AT-1030, Austria
Proteomics Centre, Institute of Biochemistry, Vilnius University, 01513 Vilnius, Lithuania
MAP Kinase Resource, Bioinformatics, Melchiorstrasse 9, CH-3027 Bern, Switzerland
Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania
Department of Biology and Chemistry, Lithuanian University of Educational Sciences, 08106 Vilnius, Lithuania
Cardiovascular Research Centre, Viborg Hospital, Heibergs Alle 4, 8800 Viborg, Denmark
Author to whom correspondence should be addressed.
Cancers 2018, 10(1), 1;
Received: 25 October 2017 / Revised: 14 December 2017 / Accepted: 19 December 2017 / Published: 21 December 2017
(This article belongs to the Collection Kinases and Cancer)
Mitogen-activated protein kinases (MAP kinases) are a family of kinases that regulates a range of biological processes implicated in the response to growth factors like latelet-derived growth factor (PDGF), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and stress, such as ultraviolet irradiation, heat shock, and osmotic shock. The MAP kinase family consists of four major subfamilies of related proteins (extracellular regulated kinases 1/2 (ERK1/2), c-Jun N-terminal kinase (JNK), p38, and extracellular regulated kinase 5 (ERK5)) and regulates numerous cellular activities, such as apoptosis, gene expression, mitosis, differentiation, and immune responses. The deregulation of these kinases is shown to be involved in human diseases, such as cancer, immune diseases, inflammation, and neurodegenerative disorders. The awareness of the therapeutic potential of the inhibition of MAP kinases led to a thorough search for small-molecule inhibitors. Here, we discuss some of the most well-known MAP kinase inhibitors and their use in cancer research. View Full-Text
Keywords: JNK; p38; ERK; SGK1; kinase inhibitors; cancer; MAP kinases JNK; p38; ERK; SGK1; kinase inhibitors; cancer; MAP kinases
Show Figures

Figure 1

MDPI and ACS Style

Cicenas, J.; Zalyte, E.; Rimkus, A.; Dapkus, D.; Noreika, R.; Urbonavicius, S. JNK, p38, ERK, and SGK1 Inhibitors in Cancer. Cancers 2018, 10, 1.

AMA Style

Cicenas J, Zalyte E, Rimkus A, Dapkus D, Noreika R, Urbonavicius S. JNK, p38, ERK, and SGK1 Inhibitors in Cancer. Cancers. 2018; 10(1):1.

Chicago/Turabian Style

Cicenas, Jonas, Egle Zalyte, Arnas Rimkus, Dalius Dapkus, Remigijus Noreika, and Sigitas Urbonavicius. 2018. "JNK, p38, ERK, and SGK1 Inhibitors in Cancer" Cancers 10, no. 1: 1.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop